Stockscreener 앱 받기
366.54
2.42%
-9.09
시장 영업 전:
369.98
3.44
+0.94%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
The week in pharma: action, reaction and insight – week to August 8 - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN
KOL Views: Vertex's triplet data exceed expectations – implications for CF landscape - FirstWord Pharma
Vertex Analyst Rating Lowered by B of A Securities; VERX Stock Price Target Cut to $34.00 - AInvest
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com
Hedge Fund and Insider Trading News: Ken Griffin, DE Shaw, Bobby Jain, Jim Cramer, Rokos Capital Management, Point72 Asset Management, Vertex Pharmaceuticals Inc (VRTX), Galaxy Digital Inc (GLXY), and More - Insider Monkey
Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener
Stock Analysis | Vertex Pharmaceuticals OutlookNavigating Mixed Signals and Market Uncertainty - AInvest
Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com
RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener
Vertex Pharmaceuticals Executives Make Significant Stock Purchases - TradingView
Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest
The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media
Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN
Vertex’s Journavx successor culled after falling short in Phase II trial - Yahoo Finance
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - MSN
Vertex Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks
Vertex falls after FDA doubts broad use of chronic pain drug - The Boston Globe
Vertex Pharmaceuticals Reports 12% Revenue Increase in Q2 2025 - The Globe and Mail
Growing, pain: Journavx on the move as Vertex reports 2Q hitches - BioWorld MedTech
Vertex Pharmaceuticals Halts Development of VX-993 After Phase II Trial Fails to Show Pain Relief Benefit - geneonline.com
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today - Yahoo Finance
Vertex Pharmaceuticals stock hits 52-week low at $377.78 - Investing.com
Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga
Cantor Equity Partners, Inc. shares fall 2.41% intraday as Vertex Pharmaceuticals' price targets are adjusted by multiple analysts. - AInvest
Vertex stock price target lowered to $478 at H.C. Wainwright on pain program setbacks - Investing.com Australia
Vertex Pharmaceuticals: A Long-Term Growth Story Fueled by Financial Discipline and Pipeline Breakthroughs - AInvest
Vertex’s strong quarter unable to undo pain from VX-993 woes - The Pharma Letter
VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial - TradingView
Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain - Patient Care Online
Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq
Vertex Non-Opioid Pain Drug Flunks Proof-of-Concept Test, Ending Plans for a Pivotal Study - MedCity News
Vertex Pharmaceuticals Stock Falls 15% After Failed Drug TrialNews and Statistics - IndexBox
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal - Yahoo Finance
Vertex Pharmaceuticals' Q2 2025 Earnings and JOURNAVX Strategy Discrepancies: Assessing Long-Term Viability Amid Short-Term Volatility - AInvest
Vertex Pharmaceuticals: Navigating Short-Term Setbacks to Unlock Long-Term Value in a High-Stakes Biotech Landscape - AInvest
Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain - Fierce Pharma
Vertex Pharma plunges as trial setback overshadows Q2 beat - Seeking Alpha
Vertex Falls After FDA Doubts Broad Use of Chronic Pain Drug - Bloomberg.com
Nasdaq 100 Movers: Axon Enterprise Leads Gains, Vertex Pharmaceuticals Declines - AInvest
Vertex’s Pain Drug Failure Adds To Investor Doubts - insights.citeline.com
Novo and Hims seem to give conflicting accounts on compounding demand - statnews.com
Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors. - Barron's
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug - Investopedia
Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers - Yahoo Finance
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings - BioSpace
Vertex is smarting from a pain portfolio setback - pharmaphorum
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity By Stocktwits - Investing.com India
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity - Stocktwits
Pipeline Milestones and Setbacks Could Be a Game Changer for Vertex Pharmaceuticals (VRTX) - simplywall.st
Vertex Pharmaceuticals Chief Scientific Officer David Altshuler to Retire in 2024 After Nearly a Decade of Leadership - geneonline.com
0.57%
1.56%
자본화:
|
볼륨(24시간):